pand the collection base, especially in regards to new revenue sources in line with

Rate this Entry
Continued Research Makes Biotherapeutics Cell Line Development Market a Highly Attractive Space Health Articles | October 3 Wholesale Ferguson Jenkins Jersey , 2016

With the increasing number of recombinant protein therapeutics gaining approval by the U.S. Food and Drug Administration (FDA) annually, there is an increase in the demand of cell lines for production of these biotherapeutics.

Insulin, which helps millions of diabetics worldwide to regulate their blood sugar levels, holds the distinction of being the first modern medicine to be produced using biotechnological methods. Since the last three decades, the demand for biotherapeutics has shown a steep upward growth trajectory because there is now a greater demand for treating serious diseases such as cancer, rheumatoid arthritis, and multiple sclerosis.

Request free Sample pages of premium Research Report:

This rising demand for biotherapeutics, coupled with several biopharmaceutical drugs nearing late-stage clinical trials, has consequently created appreciable demand for cell line development. Thatís because an appreciable number of biotherapeutics are recombinant monoclonal antibodies produced in mammalian cell lines. While producing cell lines wasnít a commercially feasible process until a few years ago, that scenario has long changed. Advances in biotechnology now enable biotech and life sciences companies to produce cell line on a large scale for protein-based therapeutics.

The global biotherapeutics cell line development market had a valuation of US$56.03 mn as of 2014. As per the projections of Transparency Market Research, the market is expected to rise to US$99.84 mn by 2022. This translates to a compounded annual growth (CAGR) rate of 7.5% between 2015 and 2022.

What do the numbers speak of the demand for biotherapeutics cell line development market?

The number of recombinant protein therapeutics approved by the United Statesí Food and Drug Administration (FDA) has only risen with every passing year. Taking this rise into consideration, there is a parallel increase in the demand for cell lines to produce biotherapeutics. In 2014, for instance, 11 novel recombinant protein therapeutics received FDAís stamp of approval. From 2006 to 2011, TMR analysts say that on an average, 15 novel recombinant drugs were approved by the US FDA.

In the U.S., Europe, and other important global markets, the number of monoclonal antibody products approved approximates 47. Of these, more than 60% were reportedly produced in mammalian cell culture.

North America, Europe, and Asia Pacific: The Largest Biotherapeutics Cell Line Development Markets, in that Order

North Americaís leading position in the global biotherapeutics cell line development market in 2014 can be ascribed to the presence of a number of large biopharmaceutical manufacturers here. The expanding geriatric population base here also presents a massive opportunity for the biotherapeutics industry. Europe, the second-largest market for biotherapeutics cell line development has remained firmly on the growth track thanks to a rising demand for biotherapeutics.

View exclusive Global strategic Business report :聽

However, the future of the biotherapeutics cell line development market lies in Asia Pacific, which was ranked as the third-largest market globally. The potential that APAC presents can be gauged from the prediction that the region will exhibit the highest CAGR globally. This, coupled with considerable investments made by large multinationals in countries such as China and India will make the market worth tracking. Latin America is yet another high-potential market for biotherapeutics cell line development. Countries such as Brazil, especially are emerging as attractive markets for biotherapeutics cell line development.

Contact us:

Transparency Market Research

90 State Street,

Suite 700,


NY - 12207

United States

Tel: +1-518-618-1030

USA - Canada Toll Free 866-552-3453



HANOI, Sept. 22 (Xinhua) -- Vietnam's public debt was 94 billion U.S. dollars by the end of 2015, or 61 percent of its gross domestic product (GDP), local media on Friday quoted the country's Finance Ministry as reporting.

Of the public debt, external debt was over 39.6 billion dollars, and internal debt was more than 54 billion dollars, daily newspaper Tuoi Tre (Youth) cited the ministry's latest public debt bulletin.

In 2015, the Vietnamese government borrowed total loans of 52 billion dollars, mostly internal debt, much higher than the figure in 2011.

Meanwhile, the government paid over 13.3 billion dollars to creditors, mostly local ones.

Since 2013, the government has borrowed money mostly from internal sources, limiting its external debt.

Vietnam's budget revenue over GDP decreased from 26.3 percent in the 2006-2010 period to 23.6 percent of GDP between 2011 and 2016, newspaper Nhan Dan (People) quoted Vietnamese Finance Minister Dinh Tien Dung as saying.

The country's tax policy system will be revised to cover all revenue sources and expand the collection base, especially in regards to new revenue sources in line with international practice.

Vietnam is trying to keep its public debt below 65 percent of GDP between 2016 and 2018, online newspaper VietNamNet reported.

Chinese, Australian armies conclude joint training exercise

Aftermath of 7.1-magnitude earthquake in Mexico City

Sacrifice ceremony for late Thai king held in Bangkok

Dominica PM confirms at least 15 killed in hurricane Maria attack

Highlights of 10th China Acrobatics. Cheap NBA Jerseys Cheap NFL Jerseys China Cheap NFL Jerseys Wholesale Cheap NFL Jerseys From China Cheap NFL Jerseys Wholesale Cheap NFL Nike Jerseys Cheap NFL Football Jerseys Cheap NFL Football Jerseys Cheap NFL Nike Jerseys Wholesale NFL Jerseys
Tags: None Add / Edit Tags